Healthcare Spending Policy

U.S. healthcare spending exceeded $4.5 trillion in 2023 — approximately 18% of GDP and roughly twice the per-capita spending of comparable high-income countries — making it the world's most expensive healthcare system by a wide margin. This spending flows through four primary channels: Medicare (the federal program for adults 65+ and the disabled, covering approximately 66 million people at roughly $1 trillion/year), Medicaid (the federal-state program for low-income individuals, covering approximately 90 million people at roughly $900 billion/year combined federal-state), private insurance (primarily employer-sponsored, covering approximately 160 million people), and out-of-pocket spending (deductibles, copays, and uninsured expenditures). The federal government directly funds over 45% of total healthcare spending through Medicare, Medicaid, CHIP, VA healthcare, and the federal employee benefits program — making it the dominant purchaser and, consequently, the dominant price-setter in healthcare markets. Healthcare's share of GDP has risen from 5% in 1960 to 18% today, driven by an aging population, increased chronic disease burden, medical technology advances, administrative complexity, and structural features of U.S. markets that limit price competition. The Affordable Care Act (2010) extended coverage to approximately 25 million previously uninsured Americans but did not fundamentally reduce per-capita costs. Policy debates center on whether coverage expansions, price transparency mandates, drug pricing reforms, value-based payment models, or more fundamental restructuring can bend the cost curve.

Current Law (2026)

U.S. healthcare spending exceeds $4.5 trillion/year (~18% of GDP), funded by a mix of government programs, employer insurance, and individual spending.

Key Policy Levers

• Medicare negotiation: IRA authorized Medicare drug price negotiation for the first time. See Medicare Drug Price Negotiation.
• ACA subsidies: Premium tax credits and cost-sharing reductions. See ACA Premium Tax Credits.
• Provider payment: Medicare/Medicaid reimbursement rates affect provider participation and access. See Medicare Part D Premium for prescription drug costs.
• Emergency care mandate: EMTALA requires hospitals to treat all emergency patients regardless of ability to pay, creating billions in uncompensated care costs.
• Surprise billing: No Surprises Act protections. See Surprise Billing Protections.
• Prescription drug costs: Drug pricing reform is the most active healthcare spending policy area.

How It Affects You

If you get health insurance through an employer: The average employer-sponsored family plan costs over $23,000/year in 2026, with employees paying roughly $6,500 in premiums plus another $1,500–$3,000 in out-of-pocket costs on average. When underlying care costs rise, employers typically raise deductibles first, narrow networks second, and raise premium contributions last. You have more options than most people realize during open enrollment: compare plans on actuarial value (the estimated share of costs the plan covers), the out-of-pocket maximum (your worst-case annual exposure), and the total cost (your premium share + expected out-of-pocket) — not just the monthly premium. If your employer offers a high-deductible health plan (HDHP) that qualifies for an HSA, you can put pre-tax money into a health savings account — $4,300 individual / $8,550 family in 2026 — reducing your effective health cost by your marginal tax rate. For a moderate healthcare user in the 22% bracket, the tax savings on an HSA contribution alone ($946/year individual) can offset a significant portion of a higher deductible. Your HR department's benefits decision tool typically models total expected cost across plan options — ask for it during open enrollment.

If you buy coverage on the ACA marketplace: The 2026 marketplace is materially more expensive for households above 400% FPL (~$62,600 for a single adult, ~$128,600 for a family of four) because the enhanced Premium Tax Credits expired after 2025. Unsubsidized Silver benchmark premiums for a 50-year-old can exceed $800–900/month in many states — a premium cliff that catches early retirees and self-employed people hardest. Three strategies if you're near or above the cliff: (1) MAGI management — traditional IRA contributions ($7,000/$8,000 if 50+), HSA contributions ($4,300/$8,550), and pre-tax retirement account contributions all reduce Modified Adjusted Gross Income, potentially pushing you below the 400% FPL threshold for subsidy eligibility; (2) State-based supplements — California (coveredca.com), New York (nystateofhealth.ny.gov), Massachusetts, and Colorado maintain state-funded supplement programs that partially cushion the federal cliff; (3) Plan tier selection — if you do qualify for subsidies, Bronze-tier plans can have near-$0 premiums when PTC fully covers the benchmark; Silver plans trigger cost-sharing reductions below 250% FPL. Enroll or update at healthcare.gov (Open Enrollment November 1–January 15).

If you're on Medicare: The IRA's drug price negotiation directly affects your Part D out-of-pocket costs starting in 2026. The first ten negotiated drugs — including Eliquis, Jardiance, Xarelto, and Farxiga for blood clots, diabetes, and heart failure — have Maximum Fair Prices significantly below prior list prices. If you take one of these drugs, you should see lower cost-sharing automatically; verify your plan covers the drug and at what tier at medicare.gov/plan-compare (search by drug and zip code). The $2,000 annual Part D out-of-pocket cap (effective 2026 under the IRA, separate from the drug negotiation) is the more broadly impactful change: no Medicare beneficiary pays more than $2,000/year for covered Part D drugs regardless of drug cost. If you've historically paid more in a calendar year, the cap reduces your drug spending automatically starting January 1, 2026 — no action needed. Use the Annual Enrollment Period (October 15 – December 7) to switch to the Part D or Medicare Advantage plan that best covers your specific drugs; the Plan Finder at medicare.gov compares your actual drugs across all local plans.

If you're on Medicaid: Medicaid reimbursement rates — set by states within federal guidelines — frequently fall below the cost of providing care, which is why some specialists, dentists, and behavioral health providers limit or refuse Medicaid patients. This is a structural funding problem, not a paperwork one. If you're having persistent trouble finding an in-network provider: (1) Federally Qualified Health Centers are required to serve all patients regardless of ability to pay, charge sliding-scale fees, and serve all Medicaid enrollees — find the nearest FQHC at findahealthcenter.hrsa.gov or call 1-877-464-4772; (2) Managed care plan comparison — if your state uses Medicaid managed care organizations (most do), different plans have different provider networks; you can usually switch plans once per year through your state Medicaid agency, and switching to a plan with a broader network can solve the access problem; (3) State Medicaid member services — your state's Medicaid agency maintains a member services line that can identify in-network specialists; find your state contact at medicaid.gov/about-us/contact-us. For dental, vision, and behavioral health — which Medicaid covers in some states but not others — confirm your state's full benefits package before assuming non-coverage.

Implementing Regulations

Healthcare spending policy spans multiple agencies. Key implementing regulations include 42 CFR Parts 400–499 (CMS — Medicare/Medicaid program requirements), 45 CFR Parts 155–156 (ACA marketplace standards), and 26 CFR Part 1 (ACA individual/employer mandate, premium tax credits). OMB and CBO produce spending projections and analyses under internal methodologies.

Pending Legislation

• S 3385 — Lower Health Care Costs Act: extends enhanced ACA premium tax credits and 400% poverty-line eligibility window through 2028. Status: Introduced.
• S 3389 — Lowering Health Care Costs for Americans Act: caps monthly premium tax credits, creates Healthcare Affordability Accounts, forces broad price and billing transparency for hospitals, labs, and plans. Status: Introduced.
• S 1818 — Prescription Drug Price Relief Act of 2025: forces HHS reviews of brand drug prices, voids exclusivities for excessive prices, opens licensing with royalties. Status: Introduced.
• S 3751 — Prescription Drug Supply Chain Pricing Transparency Act: requires GAO study of price-based fees and conflicts across the Rx supply chain. Status: Introduced.
• HR 7391 — Community Health Center Drug Pricing Protection Act: bars deals that make community health centers pay above the 340B price. Status: Introduced.
• S 2617 (Sen. Rosen, D-NV) — Reducing Drug Prices for Seniors Act: shifts Part D coinsurance from list prices to negotiated net prices. Status: Introduced.
• HR 4605 (Rep. Nadler, D-NY) — End Prescription Drug Ads Now Act: would stop or limit consumer-facing prescription drug ads. Status: Introduced.
• H Res 928 — Resolution backing most-favored-nation drug pricing for U.S. patients. Status: Introduced.

Recent Developments

• U.S. healthcare spending surpassed $4.5 trillion in 2023 — the highest in the world by any measure: The Centers for Medicare & Medicaid Services (CMS) National Health Expenditure data for 2023 showed U.S. healthcare spending at approximately $4.5 trillion, or ~17.3% of GDP. Per capita spending exceeds $13,000/year — roughly twice that of other high-income countries. Federal government programs (Medicare, Medicaid, CHIP, VA, and federal employees' benefits) account for approximately 35% of total health expenditure. Despite high spending, U.S. health outcomes by most metrics rank below peer nations.
• IRA Medicare drug price negotiation delivering first savings in 2026: The Inflation Reduction Act (2022) authorized Medicare to negotiate drug prices directly with manufacturers for the first time. The first ten drugs (including blood thinners, cancer drugs, and diabetes medications) were negotiated in 2023-2024, with negotiated prices effective January 1, 2026. CMS projects substantial savings for Medicare and beneficiaries — the negotiated prices are significantly below current market rates. The pharmaceutical industry filed multiple legal challenges, all of which were rejected by courts. This represents the most significant change to Medicare drug pricing in the program's history.
• Enhanced ACA subsidies expired — marketplace enrollment impact: The enhanced Premium Tax Credits enacted under the American Rescue Plan (2021) and extended through 2025 expired at year-end 2025. As a result, 2026 marketplace premiums for consumers above 400% FPL are no longer fully capped at 8.5% of income. States that added their own bridge subsidies (CA, NY, MA, CO) have partially offset the federal cliff, but most other states saw significant premium increases for affected enrollees. Early 2026 open enrollment data suggests some consumers dropped or downgraded coverage.
• Medicaid under reconciliation pressure in 2025: The 119th Congress's reconciliation process included proposals to convert Medicaid to block grants or cap per-capita spending — changes that would reduce federal Medicaid spending and shift fiscal risk to states. None of the proposals passed in the 2025 session. However, the debate has intensified at the state level, with multiple Republican-led states proposing work requirements (which face APA legal challenges) and other eligibility restrictions as conditions of continued expansion. Medicaid covers approximately 90 million Americans and remains the largest single payer of long-term care in the U.S.